Recordati (0KBS)
London Exchange · UK · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 53.00 |
|---|---|
| 52-week range | 43.18 – 53.65 |
| Return, 1 month / 3 months | +0.4% / +3.2% |
| Return, 1 year / 3 years | +4.1% / +30.4% |
| Trend | Uptrend |
| RSI (14) | 56 |
| Volatility (1 year) | 17.0% |
| Worst drawdown (1 year) | -15.8% |
| Average daily value traded | 5.13M EUR |
| Dividend yield | 2.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Recordati is an Italian pharmaceutical company based in Milan that develops and markets prescription medicines. It concentrates on specialty pharmaceuticals and treatments for rare diseases, with products used in cardiovascular, urological and other therapeutic areas. The company sells through its own commercial network and through partners in many countries, serving doctors, hospitals and patients across Europe and beyond. Its business combines its own research with licensed and acquired products.
On this site Recordati appears as a stock on the London Exchange (UK), code 0KBS, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Recordati (0KBS) trades on the London Exchange in UK. It last closed at EUR 53.00 on 19 October 2026.
Its price-based Market X-Ray is 73 out of 100 (a strong price profile), ranking 314 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 4.1% and over the last three months it rose 3.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 76 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 6.2% | ||
| From 52-week high | -0.9% | ||
| Momentum | 60 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 3.2% | ||
| 6-month return | 9.2% | ||
| 12-month return, skipping the last month | 3.7% | ||
| Risk (lower is better) | 88 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility (1 year) | 17.0% | ||
| Worst drawdown (1 year) | -15.8% | ||
| Liquidity | 68 · Fair | Moderate trading activity. | |
| Average daily value traded | 5.13M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 75 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 2.5% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Risk (lower is better): Calmer than most: low volatility and shallow drawdowns.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +0.4% |
| 3 months | +3.2% |
| 6 months | +9.2% |
| 1 year | +4.1% |
| 3 years | +30.4% |
| 5 years | +17.0% |
Signals
| 50-day / 200-day average | 52.65 / 49.92 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.21 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 May 2026 | EUR 0.7100 |
| 24 Nov 2025 | EUR 0.6300 |
| 19 May 2025 | EUR 0.6700 |
| 18 Nov 2024 | EUR 0.6000 |
| 20 May 2024 | EUR 0.6300 |
| 20 Nov 2023 | EUR 0.5700 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.